Tumor markers in patients with relapse of colorectal carcinoma

Anticancer Res. 2007 Jul-Aug;27(4A):1901-5.

Abstract

Aim: To evaluate CEA and CA19-9 in a long-term follow-up after radical surgery for colorectal cancer.

Patients and methods: A total of 1,090 patients were operated on for colorectal cancer, 716 patients underwent R0 resection, 631 patients were under further surveillance, relapse was diagnosed in 122 patients (20%), 74 patients were indicated for reoperation The resectability of the relapse was 35%. An AxSYM instrument (Abbott) was used for analysis.

Results: At the time of relapse both markers were normal in 31% of the patients. When relapse was diagnosed, in patients with normal preoperative levels, CEA and CA19-9 were below cut-off in 48% and 79%, respectively, and in those with primary elevation, they were again elevated in 78% and 64%, respectively.

Conclusion: The surveillance based only on CEA and/or CA19-9 was cost-effective, but failed to disclose 1/3 of patients suffering from relapse; these markers must be combined with liver and chest imaging methods and colonoscopy.

MeSH terms

  • Biomarkers, Tumor / blood*
  • CA-19-9 Antigen / blood
  • Carcinoembryonic Antigen / blood
  • Colorectal Neoplasms / blood*
  • Colorectal Neoplasms / pathology*
  • Follow-Up Studies
  • Humans
  • Neoplasm Recurrence, Local / diagnosis*
  • Neoplasm Staging
  • Retrospective Studies

Substances

  • Biomarkers, Tumor
  • CA-19-9 Antigen
  • Carcinoembryonic Antigen